Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

N/A

2(66.7%)

Phase 3

1(33.3%)

3Total

N/A(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT07141017Not ApplicableRecruiting

Initial Standardized Global Review in Axial Spondyloarthritis

Role: lead

NCT03043846Completed

Treat to Target Trial in Axial Spondylo Arthritis : The TICOSPA (Tight Control in Spondyloarthritis)

Role: lead

NCT03039088Completed

PREDICT-SpA - French Epidemiological Study of the Evaluation of the Impact of Fibromyalgia in the TNF Alpha Treatment Effect in Axial Spondyloarthritis in Both Anti-TNF naïve and - Experienced Patients

Role: lead

NCT00444691Not ApplicableUnknown

Sensitivity of Echography in Arthritis

Role: lead

NCT00439283Phase 3Completed

Study of Two Schedules of Infliximab Maintenance Therapy in Ankylosing Spondylitis

Role: lead

All 5 trials loaded